XCath Secures $30 Million Series C to Improve Global Outcomes in Neurovascular Care

XCath获得3000万美元C轮融资，用于改善全球神经血管护理结果

Latest funding will support additional development and future commercialization of XCath’s endovascular surgical robot

最新融资将支持XCath的血管内手术机器人的进一步开发和未来的商业化。

HOUSTON, March 12, 2026-- XCath, a medical device company pioneering neuro-endovascular surgical robotics, announced today that it has secured $30 million in Series C funding, bringing the total raised since the company’s inception to $92 million. The round was co-led by Crescent Enterprises and by Dr.

休斯顿，2026年3月12日 —— XCath是一家开创神经血管内手术机器人技术的医疗设备公司，今天宣布已完成3000万美元的C轮融资，使公司自成立以来的总融资额达到9200万美元。本轮融资由新月企业（Crescent Enterprises）和Dr.共同领投。

Fred Moll, Chairman of the XCath Board of Directors. These latest funds will support XCath’s ongoing efforts to bring the world’s first commercially-practical endovascular robot to the market and to perform a clinical telerobotic mechanical thrombectomy..

弗雷德·莫尔，XCath董事会主席。这些最新的资金将支持XCath持续努力，将世界上首个商业实用的血管内机器人推向市场，并进行临床远程机械血栓切除术。

“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases,” said Eduardo Fonseca, Chief Executive Officer of XCath. “In 2025 the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”.

“我们感谢投资者对我们共同使命的坚定信念，即改善受血管内疾病影响患者的临床结果，”XCath首席执行官爱德华多·丰塞卡表示。“2025年，XCath团队推动了血管内机器人技术的发展。这笔资金加快了我们扩大救命治疗可及性的承诺，让患者居住的地方不再决定他们的生死。”

This latest round of financing comes on the heels of XCath’s successful first-in-human procedures using its Iris robotic system to treat patients with complex brain aneurysms in November of 2025. Those landmark procedures, conducted by Dr. Vitor Mendes Pereira at The Panama Clinic in Panama City, with local Principal Investigator Dr.

这一最新一轮融资是在XCath于2025年11月成功使用其Iris机器人系统为复杂脑动脉瘤患者进行首次人体手术之后进行的。这些具有里程碑意义的手术由维托·门德斯·佩雷拉博士在巴拿马城的巴拿马诊所进行，当地主要研究者为博士。

Anastasio Ameijeiras Sibauste, marked the second time in history that a surgical robot has been used in an intracranial neurovascular intervention and solidified XCath’s leadership position in endovascular robotics..

阿纳斯塔西奥·阿梅ije拉斯·西鲍斯特，标志着手术机器人在颅内神经血管介入手术中的第二次应用，巩固了XCath在血管内机器人领域的领导地位。

“Robotic surgery succeeds when innovation is paired with practical execution,” said Dr. Moll. “XCath has built a promising technology foundation, and just as importantly, a team that values rigor and appreciates perspective. I’m excited to support them as they take on the mission of globalizing access to gold-standard care for stroke patients.”.

“当创新与实际执行相结合时，机器人手术就会取得成功，”莫尔博士说。“XCath 建立了一个有前景的技术基础，同样重要的是，建立了一支重视严谨并具有全局观的团队。我非常期待支持他们完成让中风患者获得黄金标准护理的全球化使命。”

“Surgical robotics represents one of the most compelling long-term investment opportunities in healthcare. XCath has assembled an exceptional team of physicians, entrepreneurs and engineers, clearly focused on addressing a significant global healthcare unmet need,” said Neeraj Agrawal, XCath Board Member and Crescent Enterprises Executive Director..

“手术机器人代表了医疗保健领域最引人注目的长期投资机会之一。XCath汇集了一支由医生、企业家和工程师组成的杰出团队，明确专注于解决全球医疗保健中一个重要的未满足需求，”XCath董事会成员兼Crescent Enterprises执行董事尼拉杰·阿格拉瓦尔表示。

XCath’s Iris is the only endovascular robotic system currently in development to achieve intracranial navigation or neurointerventional treatment. It is also the only robot in the world to have performed an intracranial neurovascular procedure involving the robotic manipulation of three devices, and the only system to have operated using standard monoplane imaging equipment..

XCath的Iris是目前唯一在开发中的血管内机器人系统，可实现颅内导航或神经介入治疗。它也是世界上唯一一个执行过涉及三种设备机器人操作的颅内神经血管手术的机器人，并且是唯一一个使用标准单平面成像设备进行操作的系统。

“Treatment of stroke and other neurovascular diseases represents one of the most significant financial opportunities in healthcare, supported by positive reimbursement dynamics and strong demand from health systems. With our continued investor support and disciplined capital deployment, XCath is positioned to build a category-leading platform in endovascular robotics.' said Nicholas Drysdale, Chief Financial Officer of XCath..

“中风和其他神经血管疾病的治疗代表了医疗保健领域最显著的财务机会之一，受益于积极的报销动态和卫生系统的强劲需求。凭借我们持续的投资者支持和严谨的资本部署，XCath 有望在血管内机器人领域打造一个领先的平台。” XCath 首席财务官尼古拉斯·德莱斯代尔表示。

About XCath

关于XCath

Founded in 2017, XCath is a dynamic startup at the cutting edge of surgical robotics. With strategically located campuses in Houston, Texas – home to the world's largest medical center – and Pangyo, South Korea, often referred to as the Silicon Valley of Korea, XCath is committed to bringing its innovative solutions to patients around the world..

XCath 成立于2017年，是一家处于外科机器人技术前沿的充满活力的初创公司。公司在德克萨斯州休斯顿（这里是世界上最大的医疗中心所在地）和常被称为韩国硅谷的韩国板桥设有战略校区，XCath 致力于将其创新解决方案带给世界各地的患者。

The XCath endovascular robotic system is currently under development. It is not yet cleared for commercial distribution in any country.

XCath血管内机器人系统目前正在开发中，尚未在任何国家获得商业销售许可。

Contact:

联系：

Media:

媒体：

Media@XCath.com

媒体@XCath.com